Revance Therapeutics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Revance Therapeutics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| net cash from operating activities | -42,731,000 | -50,962,000 | -53,382,000 | -69,500,000 | -30,182,000 | -57,871,000 | -44,225,000 | -61,270,000 | -44,611,000 | -53,167,000 | -49,005,000 | -74,755,000 | -62,314,000 | -55,686,000 | -17,213,000 | -43,289,000 | -33,508,000 | -31,949,000 | -29,290,000 | -11,414,000 |
| net cash from investing activities | 2,370,000 | 51,586,000 | -39,532,000 | 95,316,000 | 40,960,000 | -118,445,000 | -105,881,000 | 44,568,000 | 27,641,000 | 16,807,000 | -35,693,000 | -38,420,000 | -8,691,000 | 32,496,000 | 93,895,000 | -105,569,000 | 30,919,000 | 918,000 | 54,012,000 | -103,441,000 |
| net cash from financing activities | -1,629,000 | 37,460,000 | 97,471,000 | 3,265,000 | -6,173,000 | 211,389,000 | 21,165,000 | 105,313,000 | 405,000 | -2,492,000 | 2,912,000 | 29,044,000 | 67,324,000 | -687,000 | 500,000 | 264,347,000 | 114,827,000 | -81,000 | 43,000 | 106,868,000 |
| capital expenditure | -1,779,000 | -4,503,000 | 266,000 | -870,000 | -1,288,000 | -1,002,000 | 536,000 | -1,456,000 | -4,357,000 | -1,002,000 | -980,000 | -4,036,000 | -257,414,000 | -777,000 | -574,000 | -657,000 | -288,000 | -1,484,000 | -375,000 | -1,091,000 |
We provide you with 20 years of cash flow statements for Revance Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Revance Therapeutics stock. Explore the full financial landscape of Revance Therapeutics stock with our expertly curated income statements.
The information provided in this report about Revance Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.